189 related articles for article (PubMed ID: 27581680)
1. Statin action enriches HDL3 in polyunsaturated phospholipids and plasmalogens and reduces LDL-derived phospholipid hydroperoxides in atherogenic mixed dyslipidemia.
Orsoni A; Thérond P; Tan R; Giral P; Robillard P; Kontush A; Meikle PJ; Chapman MJ
J Lipid Res; 2016 Nov; 57(11):2073-2087. PubMed ID: 27581680
[TBL] [Abstract][Full Text] [Related]
2. HDL3-mediated inactivation of LDL-associated phospholipid hydroperoxides is determined by the redox status of apolipoprotein A-I and HDL particle surface lipid rigidity: relevance to inflammation and atherogenesis.
Zerrad-Saadi A; Therond P; Chantepie S; Couturier M; Rye KA; Chapman MJ; Kontush A
Arterioscler Thromb Vasc Biol; 2009 Dec; 29(12):2169-75. PubMed ID: 19762782
[TBL] [Abstract][Full Text] [Related]
3. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
4. Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia.
Meikle PJ; Wong G; Tan R; Giral P; Robillard P; Orsoni A; Hounslow N; Magliano DJ; Shaw JE; Curran JE; Blangero J; Kingwell BA; Chapman MJ
J Lipid Res; 2015 Dec; 56(12):2381-92. PubMed ID: 26486974
[TBL] [Abstract][Full Text] [Related]
5. Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: Quantity vs quality over time and implication of CETP.
Chapman MJ; Orsoni A; Robillard P; Therond P; Giral P
J Clin Lipidol; 2018; 12(3):784-800.e4. PubMed ID: 29574070
[TBL] [Abstract][Full Text] [Related]
6. Small, dense high-density lipoprotein 3 particles exhibit defective antioxidative and anti-inflammatory function in familial hypercholesterolemia: Partial correction by low-density lipoprotein apheresis.
Hussein H; Saheb S; Couturier M; Atassi M; Orsoni A; Carrié A; Therond P; Chantepie S; Robillard P; Bruckert E; Chapman MJ; Kontush A
J Clin Lipidol; 2016; 10(1):124-33. PubMed ID: 26892129
[TBL] [Abstract][Full Text] [Related]
7. Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity.
de Souza JA; Vindis C; Hansel B; Nègre-Salvayre A; Therond P; Serrano CV; Chantepie S; Salvayre R; Bruckert E; Chapman MJ; Kontush A
Atherosclerosis; 2008 Mar; 197(1):84-94. PubMed ID: 17868679
[TBL] [Abstract][Full Text] [Related]
8. Effects of pitavastatin add-on therapy on chronic kidney disease with albuminuria and dyslipidemia.
Ohsawa M; Tamura K; Wakui H; Kanaoka T; Azushima K; Uneda K; Haku S; Kobayashi R; Ohki K; Haruhara K; Kinguchi S; Toya Y; Umemura S
Lipids Health Dis; 2015 Dec; 14():161. PubMed ID: 26645467
[TBL] [Abstract][Full Text] [Related]
9. Structure-function relationships in reconstituted HDL: Focus on antioxidative activity and cholesterol efflux capacity.
Cukier AMO; Therond P; Didichenko SA; Guillas I; Chapman MJ; Wright SD; Kontush A
Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Sep; 1862(9):890-900. PubMed ID: 28529180
[TBL] [Abstract][Full Text] [Related]
10. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H
J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297
[TBL] [Abstract][Full Text] [Related]
11. HDL
Chaudhary R; Kinderytė M; Chaudhary R; Sukhi A; Bliden K; Tantry U; Gurbel P
Cardiovasc Revasc Med; 2019 Nov; 20(11):1001-1006. PubMed ID: 30626544
[TBL] [Abstract][Full Text] [Related]
12. Ezetimibe decreases serum amyloid A levels in HDL3 in hemodialysis patients.
Hirano T; Nohtomi K; Nakanishi N; Watanabe T; Hyodo T; Taira T
Clin Nephrol; 2010 Oct; 74(4):282-7. PubMed ID: 20875380
[TBL] [Abstract][Full Text] [Related]
13. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
[TBL] [Abstract][Full Text] [Related]
14. Lifestyle intervention enhances high-density lipoprotein function among patients with metabolic syndrome only at normal low-density lipoprotein cholesterol plasma levels.
Hansel B; Bonnefont-Rousselot D; Orsoni A; Bittar R; Giral P; Roussel R; Marre M; Mohammedi K; Bruckert E; Chapman MJ; Kontush A
J Clin Lipidol; 2016; 10(5):1172-81. PubMed ID: 27678434
[TBL] [Abstract][Full Text] [Related]
15. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity.
Hansel B; Giral P; Nobecourt E; Chantepie S; Bruckert E; Chapman MJ; Kontush A
J Clin Endocrinol Metab; 2004 Oct; 89(10):4963-71. PubMed ID: 15472192
[TBL] [Abstract][Full Text] [Related]
16. Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities.
Kontush A; Therond P; Zerrad A; Couturier M; Négre-Salvayre A; de Souza JA; Chantepie S; Chapman MJ
Arterioscler Thromb Vasc Biol; 2007 Aug; 27(8):1843-9. PubMed ID: 17569880
[TBL] [Abstract][Full Text] [Related]
17. Effects of pancreas transplantation on distribution and composition of plasma lipoproteins.
Föger B; Königsrainer A; Palos G; Ritsch A; Tröbinger G; Menzel HJ; Lechleitner M; Doblinger A; König P; Utermann G; Margreiter R; Patsch JR
Metabolism; 1996 Jul; 45(7):856-61. PubMed ID: 8692021
[TBL] [Abstract][Full Text] [Related]
18. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
[TBL] [Abstract][Full Text] [Related]
19. Phosphatidylcholine and phosphatidylethanolamine plasmalogens in lipid loaded human macrophages.
Wallner S; Orsó E; Grandl M; Konovalova T; Liebisch G; Schmitz G
PLoS One; 2018; 13(10):e0205706. PubMed ID: 30308051
[TBL] [Abstract][Full Text] [Related]
20. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
Wong ND; Chuang J; Zhao Y; Rosenblit PD
J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
